Article
Precision cancer genome testing needs proficiency testing involving all stakeholders.
Scientific reports - 27 Jan 2022
Maekawa Masato, Taniguchi Terumi, Nishio Kazuto, Sakai Kazuko, Matsushita Kazuyuki, Nakatani Kaname, Ishige Takayuki, Ikejiri Makoto, Nishihara Hiroshi, Sunami Kuniko, Yatabe Yasushi, Hatanaka Kanako C, Hatanaka Yutaka, Yamamoto Yoshihiro, Fukuyama Keita, Oda Shinya, Saito Kayoko, Yokomura Mamoru, Kubo Yuji, Sato Hiroko, Tanaka Yoshinori, Fuchioka Misa, Yamasaki Tadashi, Matsuda Koichiro, Kurachi Kiyotaka, Funai Kazuhiro, Baba Satoshi, Iwaizumi Moriya
Abstract excerpt
To implement precision oncology, analytical validity as well as clinical validity and utility are important. However, proficiency testing (PT) to assess validity has not yet been systematically performed in Japan. To investigate the quality of next-generation sequencing (NGS) platforms and cancer genome testing prevalent in laboratories, we performed pilot PT using patient samples. We prepared genomic DNA from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
